한글목차

세계의 트랜스펙션 시약 및 장비 시장 규모는 2025년에 11억 440만 달러에 달했습니다. 향후 IMARC Group은 2026년부터 2034년까지 CAGR 6.24%를 나타내고, 2034년까지 19억 420만 달러에 달할 것으로 예측하고 있습니다.

트랜스펙션 시약 및 장비는 in vitro 및 in vivo에서 진핵세포의 유전자 발현을 조절하는 데 도움이 됩니다. 연구자가 안정된 세포주를 생성하고, 발현용 유전자 삽입이 있는 데옥시리보핵산(DNA) 플라스미드나 작은 간섭 RNA(siRNA)를 도입할 수 있습니다. 현재 단백질 합성, 세포의 성장 및 발달, 유전 기능의 연구 촉진을 위한 효과적인 분석 도구로 활용되고 있습니다. 또한, 트랜스펙션 시약 및 장비는 충분한 양의 재조합 인간 치료용 단백질을 비용 효율적이고 신속하게 생산할 수 있기 때문에 백신용 r-단백질, 항체, 바이러스 벡터의 생산에서도 주목받고 있습니다.

트랜스펙션 시약 및 장비 시장 동향:

신종 코로나바이러스 감염증(COVID-19)이 전 세계적으로 확산됨에 따라 많은 국가의 규제 당국은 백신 접종을 가속화하는 데 주력하고 있습니다. 그러나 새로운 변종 균주의 출현으로 인해 백신이 제공하는 보호 효과와 면역력은 단명하다는 것이 밝혀졌습니다. 이에 따라 바이러스 감염과 싸우기 위한 혁신적인 전략의 개발 또는 기존 치료법을 전환할 수 있는 트랜스펙션 시약 및 장비의 필요성이 증가하고 있습니다. 이와 더불어, 새로운 암 변이체의 신속한 검출, 정밀 의료 및 고품질 종양학 치료에 대한 수요 증가로 인해 암 연구 및 개발에서 트랜스펙션 시약 및 장비의 채택이 촉진되고 있습니다. 또한, 유전적 문제로 인한 희귀질환 치료에 유전자 치료의 새로운 활용이 시장 성장을 촉진하고 있습니다. 또한, 전 세계적으로 증가하는 치명적인 교통사고로 인해 손상된 조직의 기능적 대체물 개발을 위한 조직공학에 대한 수요가 크게 증가하고 있습니다. 이것이 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 이와 더불어, 최근 트랜스펙션 기술의 발전과 제약 및 생명공학 분야에 대한 투자 증가가 시장을 견인할 것으로 예상됩니다.

본 보고서에서 답변하는 주요 질문

• 2025년 세계 트랜스펙션 시약 및 장비 시장 규모는 어느 정도였습니까?
• 2026년부터 2034년까지 전 세계 트랜스펙션 시약 및 장비 시장의 예상 성장률은 어느 정도일까?
• 세계 트랜스펙션 시약 및 장비 시장을 이끄는 주요 요인은 무엇인가?
• COVID-19는 전 세계 트랜스펙션 시약 및 장비 시장에 어떤 영향을 미쳤는가?
• 제품별 세계 트랜스펙션 시약 및 장비 시장의 구성은 어떻게 되어 있는가?
• 기술별로 보면 전 세계 트랜스펙션 시약 및 장비 시장의 시장 내역은 어떻게 되는가?
• 응용 분야별로 전 세계 트랜스펙션 시약 및 장비 시장은 어떻게 구성되어 있는가?
• 최종사용자별 세계 트랜스펙션 시약 및 장비 시장의 구성은 어떻게 되어 있는가?
• 전 세계 트랜스펙션 시약 및 장비 시장의 주요 지역은 어디인가?
• 세계 트랜스펙션 시약 및 장비 시장의 주요 기업 및 플레이어는 누구인가?

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 소개

제5장 세계의 트랜스펙션 시약 및 장비 시장

제6장 시장 내역 : 제품별

제7장 시장 내역 : 기술별

제8장 시장 내역 : 용도별

제9장 시장 내역 : 최종사용자별

제10장 시장 내역 : 지역별

제11장 SWOT 분석

제12장 밸류체인 분석

제13장 Porter's Five Forces 분석

제14장 가격 분석

제15장 경쟁 구도

영문목차

The global transfection reagents and equipment market size reached USD 1,104.4 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,904.2 Million by 2034, exhibiting a growth rate (CAGR) of 6.24% during 2026-2034.

Transfection reagents and equipment help modulate gene expression in eukaryotic cells in vitro and in vivo. They allow researchers to generate stable cell lines and introduce deoxyribonucleic acid (DNA) plasmids possessing gene inserts for expression and small interfering RNA (siRNA). They are currently being used as viable analytical tools for protein synthesis, cell growth and development, and facilitating the study of genetic functions. Besides this, as they provide cost-effective and rapid production of recombinant human therapeutic proteins in sufficient quantities, transfection reagents and equipment are also gaining traction in producing r-proteins, antibodies, and viral vectors for vaccines.

Transfection Reagents and Equipment Market Trends:

Due to the outbreak of coronavirus disease (COVID-19) globally, governing agencies of numerous countries are focusing on accelerating the vaccination drive. However, due to the emergence of new variants, the protection and immunity that these vaccines provide are short-lived. As a result, there is a rise in the need of transfection reagents and equipment to develop innovative strategies or alternatively repurpose existing treatments to fight against virus infection. Apart from this, rapid detection of new cancer variants, coupled with the escalating demand for precision medicine and high-quality oncology care, are driving the adoption of transfection reagents and equipment in cancer research and drug development. Moreover, the emerging use of gene therapies to treat rare diseases caused by genetic problems is impelling the market growth. Furthermore, due to the growing number of fatal road accidents across the globe, there is a significant rise in the demand for tissue engineering to develop functional substitutes for damaged tissues. This, in turn, is propelling the market growth. Besides this, recent advancements in transfection technologies, along with increasing investments in pharmaceutical and biotechnology sectors, are anticipated to drive the market.

Key Market Segmentation:

Breakup by Product:

• Reagents
• Equipment

Breakup by Technology:

• Biochemical Based Transfection
• Physical Transfection
• Viral-Vector Based Transfection

Breakup by Application:

• Biomedical Research
• Protein Production
• Therapeutic Delivery

Breakup by End User:

• Pharmaceutical and Biotechnology Companies
• Academics and Research Institutes

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The report provides a comprehensive analysis of the competitive landscape in the global transfection reagents and equipment market with detailed profiles of all major companies, including:

• Bio-Rad Laboratories, Inc
• Lonza Group AG
• MaxCyte
• Merck Life Science
• OriGene Technologies, Inc.
• Promega Corporation
• Qiagen N.V.
• Revvity, Inc.
• Sartorius AG
• SBS Genetech
• Takara Bio Inc
• Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1.What was the size of the global transfection reagents and equipment market in 2025?
• 2.What is the expected growth rate of the global transfection reagents and equipment market during 2026-2034?
• 3.What are the key factors driving the global transfection reagents and equipment market?
• 4.What has been the impact of COVID-19 on the global transfection reagents and equipment market?
• 5.What is the breakup of the global transfection reagents and equipment market based on the product?
• 6.What is the breakup of the global transfection reagents and equipment market based on the technology?
• 7.What is the breakup of the global transfection reagents and equipment market based on the application?
• 8.What is the breakup of the global transfection reagents and equipment market based on the end user?
• 9.What are the key regions in the global transfection reagents and equipment market?
• 10.Who are the key players/companies in the global transfection reagents and equipment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Transfection Reagents and Equipment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Reagents
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Equipment
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Biochemical Based Transfection
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Physical Transfection
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Viral-Vector Based Transfection
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Application

• 8.1 Biomedical Research
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Protein Production
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Therapeutic Delivery
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End User

• 9.1 Pharmaceutical and Biotechnology Companies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Academics and Research Institutes
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Bio-Rad Laboratories, Inc
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Lonza Group AG
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 MaxCyte
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
  • 15.3.4 Merck Life Science
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 OriGene Technologies, Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Promega Corporation
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Qiagen N.V.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Revvity, Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Sartorius AG
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 SBS Genetech
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Takara Bio Inc
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Thermo Fisher Scientific Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis